The editor's roundtable: role of percutaneous coronary intervention and drug-eluting stents in patients with stable coronary heart disease.

摘要

Dr. Friedewald has received honoraria from and is a speaker for Novartis, East Hanover, New Jersey. Dr. Boden has received honoraria from and is a speaker for CV Therapeutics, Palo Alto, California; Sanofi-Aventis, Bridgewa-ter, New Jersey; and Abbott Laboratories, Abbott Park, Illinois. Dr. Stone is a member of the scientific advisory board of and has received honoraria from Abbott Vascular, Santa Clara, California; and Boston Scientific Corporation, Natick, Massachusetts. Dr. Stone is a consultant for The Medicines Company, Parsippany, New Jersey; AstraZen-eca, Wilmington, Delaware; Bristol-Meyers Squibb, New York, New York; and Eli Lilly & Company, Indianapolis, Indiana. Dr. Yancy has no relevant financial relationships to disclose. Dr. Roberts has received honoraria from and is a speaker for Merck-Schering Plough, Whitehouse Station, New Jersey; AstraZeneca; and Novartis.